Encoded Therapeutics Inc., a clinical-stage biotechnology company focused on precision genetic medicines for neurological disorders, announced the completion of a $275 million Series F financing on September 9, 2026. The round was co-led by GV and an additional healthcare fund, with support from a group of new and existing investors. The capital will help advance its lead gene therapy candidate ETX101 toward registration and expand its neurology pipeline.
Financing Details and Investor Backing
The Series F financing was co-led by GV and another healthcare fund, underscoring confidence in Encoded's clinical progress. Participating investors include ARCH Venture Partners, Braidwell LP, Farallon Capital Management, Illumina Ventures, Invus, Janus Henderson Investors, Matrix Capital Management, Nolan Capital, RTW Investments, SoftBank Vision Fund 2, and Venrock. The funding brings substantial resources to support multiple late-stage development and manufacturing activities.
Clinical Strategy for Dravet Syndrome
A major portion of the proceeds will fund the pivotal study of ETX101 in infants and young children with SCN1A-positive Dravet syndrome. The company also plans to conduct an expansion study in children and adolescents up to 18 years of age. This strategy reflects a commitment to delivering a one-time, disease-modifying treatment option for a severe epilepsy disorder.
POLARIS Data Strengthens Confidence
Recent interim data from the Phase 1/2 POLARIS trials were presented at the European Epilepsy Congress and showed substantial and sustained reductions in seizure frequency. Encouraging developmental gains were also observed in participants. These findings have strengthened the company's conviction in ETX101 and its potential to alter the course of Dravet syndrome.
Manufacturing and Pipeline Expansion
In addition to clinical development, the financing supports the commercial scale-up of Encoded's internal GMP manufacturing facility. This investment is intended to provide greater control over production quality and supply as the company prepares for potential commercialization. The funding also accelerates ETX301, a candidate for post-amputation neuroma pain, toward a planned 2027 Investigational New Drug submission.
CEO Perspective
Chief Executive Officer Kartik Ramamoorthi said the interim POLARIS data demonstrate meaningful seizure reductions and developmental improvements. He noted that the financing provides resources to advance ETX101 toward registration while building capabilities for the next stage. Ramamoorthi emphasized the broader potential of Encoded's approach to substantially change the treatment landscape for neurological disorders.
Investor Perspective
Brendan Bulik-Sullivan, General Partner at GV, described the clinical profile of ETX101 as increasingly compelling with durable seizure control and promising neurodevelopmental signals. David Schenkein, General Partner and Co-Lead of Life Sciences at GV, added that progress with ETX101 validates Encoded's differentiated approach to genetic medicine. Both investors expressed confidence in Encoded's ability to build a significant portfolio of medicines across neurological diseases.
About Encoded Therapeutics
Encoded Therapeutics is a clinical-stage biotechnology company developing one-time precision genetic medicines for severe monogenic and common neurological disorders. Its vector engineering platform enables targeted and cell-type-selective control of gene expression in the brain and peripheral nervous system. The company's integrated innovation engine spans discovery, development, and internal GMP manufacturing to streamline development of one-time treatments.
The $275 million Series F financing provides Encoded Therapeutics with significant resources to advance its lead gene therapy and prepare for commercialization. By combining clinical development, internal manufacturing, and pipeline expansion, the company aims to address serious neurological conditions with precision genetic medicines. The investment highlights growing confidence in Encoded's ability to deliver durable and transformative treatment options for patients and families.